These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 29714535)
21. A qualitative approach to signal mining in pharmacovigilance using formal concept analysis. Lillo-Le Louët A; Toussaint Y; Villerd J Stud Health Technol Inform; 2010; 160(Pt 2):969-73. PubMed ID: 20841828 [TBL] [Abstract][Full Text] [Related]
22. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? Michel C; Scosyrev E; Petrin M; Schmouder R Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371 [TBL] [Abstract][Full Text] [Related]
23. Comparison of two drug safety signals in a pharmacovigilance data mining framework. Tubert-Bitter P; Bégaud B; Ahmed I Stat Methods Med Res; 2016 Apr; 25(2):615-29. PubMed ID: 23070598 [TBL] [Abstract][Full Text] [Related]
24. Disproportionality analysis for identification of drug safety signals in a database shared by the Norwegian network of drug information centres (RELIS). Stokes CL; Schjøtt J Eur J Clin Pharmacol; 2019 Oct; 75(10):1469-1470. PubMed ID: 31300837 [No Abstract] [Full Text] [Related]
25. Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System. Suzuki S; Imai S; Mitsuboshi S; Kizaki H; Hashiguchi M; Hori S J Clin Pharmacol; 2023 Aug; 63(8):903-908. PubMed ID: 37042319 [TBL] [Abstract][Full Text] [Related]
26. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Caster O; Juhlin K; Watson S; Norén GN Drug Saf; 2014 Aug; 37(8):617-28. PubMed ID: 25052742 [TBL] [Abstract][Full Text] [Related]
27. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A; Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412 [TBL] [Abstract][Full Text] [Related]
29. A conceptual approach to the masking effect of measures of disproportionality. Maignen F; Hauben M; Hung E; Holle LV; Dogne JM Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):208-17. PubMed ID: 24243699 [TBL] [Abstract][Full Text] [Related]
30. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease. Chrétien B; Jourdan JP; Davis A; Fedrizzi S; Bureau R; Sassier M; Rochais C; Alexandre J; Lelong-Boulouard V; Dolladille C; Dallemagne P Br J Clin Pharmacol; 2021 Jul; 87(7):2830-2837. PubMed ID: 33274491 [TBL] [Abstract][Full Text] [Related]
31. Application of data mining techniques in pharmacovigilance. Wilson AM; Thabane L; Holbrook A Br J Clin Pharmacol; 2004 Feb; 57(2):127-34. PubMed ID: 14748811 [TBL] [Abstract][Full Text] [Related]
32. Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection. Trinh NTH; Solé E; Benkebil M Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):370-376. PubMed ID: 29992679 [TBL] [Abstract][Full Text] [Related]
33. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use. Caster O; Sandberg L; Bergvall T; Watson S; Norén GN Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):1006-1010. PubMed ID: 28653790 [TBL] [Abstract][Full Text] [Related]
34. A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system. Noguchi Y; Ueno A; Otsubo M; Katsuno H; Sugita I; Kanematsu Y; Yoshida A; Esaki H; Tachi T; Teramachi H BMC Bioinformatics; 2018 Apr; 19(1):124. PubMed ID: 29621976 [TBL] [Abstract][Full Text] [Related]
35. Considerations on the use of different comparators in pharmacovigilance: A methodological review. Gravel CA; Douros A Br J Clin Pharmacol; 2023 Sep; 89(9):2671-2676. PubMed ID: 37226576 [TBL] [Abstract][Full Text] [Related]
36. Mining heterogeneous networks with topological features constructed from patient-contributed content for pharmacovigilance. Yang CC; Yang H Artif Intell Med; 2018 Aug; 90():42-52. PubMed ID: 30093253 [TBL] [Abstract][Full Text] [Related]
37. Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics. Hauben M Pharmacotherapy; 2004 Sep; 24(9):1122-9. PubMed ID: 15460172 [TBL] [Abstract][Full Text] [Related]
38. Multinomial modeling and an evaluation of common data-mining algorithms for identifying signals of disproportionate reporting in pharmacovigilance databases. Johnson K; Guo C; Gosink M; Wang V; Hauben M Bioinformatics; 2012 Dec; 28(23):3123-30. PubMed ID: 23064001 [TBL] [Abstract][Full Text] [Related]
39. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis. Hauben M; Vegni F; Reich L; Younus M Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161 [TBL] [Abstract][Full Text] [Related]
40. A shrinkage-based comparative assessment of observed-to-expected disproportionality measures. Gipson G Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):589-96. PubMed ID: 22290739 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]